Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19016213 | 0.94 | ALDH1A1 (0.41) | TSHRL3MBTL1MAP4K4ALDH1A1CARM1 | |
| SCHEMBL19008167 | 0.88 | ALDH1A1 (0.45) | TSHRMAP4K4ALDH1A1CARM1PRMT6 | |
| SCHEMBL18626597 | 0.88 | ALDH1A1 (0.49) | TSHRMAP4K4ALDH1A1KDM4EPOLB | |
| SCHEMBL19008163 | 0.87 | LMNA (0.37) | TSHRMAP4K4ALDH1A1CARM1PRMT6 | |
| SCHEMBL18626596 | 0.84 | MAP4K4 (0.45) | TSHRMAP4K4ALDH1A1CARM1PRMT6 | |
| SCHEMBL15587409 | 0.83 | MAP4K4 (0.47) | CHEK1MAP4K4CARM1PRMT6OPRL1 | |
| SCHEMBL19008146 | 0.82 | MAP4K4 (0.44) | TSHRMAP4K4ALDH1A1CARM1PRMT6 | |
| SCHEMBL15587596 | 0.81 | TSHR (0.46) | TSHRL3MBTL1CHEK1MAP4K4ALDH1A1 | |
| SCHEMBL19008155 | 0.80 | MAP4K4 (0.46) | MAP4K4ALDH1A1CARM1PRMT6KDM4E | |
| SCHEMBL19008147 | 0.78 | ALDH1A1 (0.47) | TSHRL3MBTL1CHEK1ALDH1A1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | TSHR 3415/4885L3MBTL1 3580/4885CHEK1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.